What is angioimmunoblastic T-cell lymphoma?
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and usually aggressive cancer of the lymphatic system. It develops from a special type of white blood cell called a T follicular helper (TFH) cell, which normally helps B cells make antibodies.
AITL is one of the most common types of peripheral T-cell lymphoma (PTCL) in Europe and North America, making up about 15-30% of PTCL cases. Overall, it accounts for only about 1-2% of all non-Hodgkin lymphomas (Lunning and Vose, 2017).
It mainly affects older adults, with a typical age at diagnosis of about 65 years.
AITL is known for causing widespread immune problems as well as swollen lymph nodes. People often have rashes, fevers, fluid build-up and abnormal blood tests that can look like an infection or autoimmune disease. This is why it has been called “the many-faced lymphoma”.
In the latest WHO classification, AITL is called nodal T-follicular helper cell lymphoma, angioimmunoblastic type (Alaggio et al., 2022).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Peripheral (mature) T-cell non-Hodgkin lymphoma |
| Cell of origin | T follicular helper (TFH) cells |
| Typical age | Median about 65 years; slightly more common in men |
| Typical stage | Usually advanced (stage III-IV) at diagnosis |
| Key symptoms | Swollen lymph nodes, fever, night sweats, rash, itching |
| Typical blood findings | Anaemia, raised antibodies, eosinophilia, positive Coombs test |
| Gene changes | TET2, RHOA G17V, DNMT3A, IDH2 |
| First treatment | CHOP-type chemotherapy, sometimes with brentuximab vedotin; stem cell transplant in some |
| Outlook | About 4 in 10 alive at 5 years |
2. AITL and related lymphomas
AITL belongs to a family of lymphomas that all come from T follicular helper cells. They share many features and gene changes, and doctors sometimes find it hard to separate them.
| Lymphoma | Main features |
|---|---|
| Angioimmunoblastic type (AITL) | The most common type; typical blood vessel and immune cell pattern |
| Follicular type | Tumour cells grow in nodules resembling normal follicles |
| Not otherwise specified (NOS) | TFH features without the full AITL or follicular pattern |
These lymphomas are generally treated in the same way. In the large French GELA series of 157 patients, most people had advanced disease, B symptoms and abnormal blood tests at diagnosis, showing how often AITL affects the whole body (Mourad et al., 2008).
3. Causes and risk factors
The exact cause of AITL is not known. It is not infectious and not inherited.
| Factor | Explanation |
|---|---|
| Age | Risk rises with age; most people are over 60 |
| Clonal haematopoiesis | Age-related gene changes (TET2, DNMT3A) in blood stem cells may be an early step |
| Additional changes | RHOA G17V and IDH2 mutations in the lymphoma cells drive the disease |
| Epstein-Barr virus (EBV) | Often found in B cells within the lymphoma; seems to reflect immune disruption rather than being the cause |
Researchers now think that AITL often starts with changes in blood stem cells years before the lymphoma appears. This may explain why some people with AITL also develop other blood disorders.
4. How does it look
On the body
| Feature | Description |
|---|---|
| Lymph nodes | Swollen nodes in several areas: neck, armpits, groin, chest and abdomen |
| Skin | A widespread red, measles-like or blotchy rash in about half of patients, sometimes itchy |
| Spleen and liver | Often enlarged |
| Fluid build-up | Swelling of the legs or fluid in the chest or abdomen |
| Joints | Occasionally swollen or painful |
The rash can come and go and is sometimes first thought to be a drug reaction or allergy.
On scans
A PET-CT scan usually shows many enlarged, active lymph nodes above and below the diaphragm, often with an enlarged spleen. Bone marrow involvement is common.
Under the microscope
| Feature | Description |
|---|---|
| Lymph node structure | Normal pattern lost; tumour spreads beyond the node capsule |
| Blood vessels | Many small, branching high endothelial venules (the “angio” in the name) |
| Mixed cells | Small tumour T cells with clear cytoplasm, plus many reactive cells: eosinophils, plasma cells, B immunoblasts |
| Follicular dendritic cells | Expanded meshworks seen with CD21 or CD23 stains |
| TFH markers | Tumour cells express PD-1, CXCL13, ICOS, BCL6 and often CD10 |
| EBV | Scattered EBV-positive B cells in most cases |
Because the tumour cells are often outnumbered by normal immune cells, AITL can be hard to diagnose. An excision biopsy of a whole lymph node is preferred over a small needle sample.
5. Symptoms
Common symptoms
- Painless swollen lymph nodes in several places
- Fever without infection
- Drenching night sweats
- Weight loss of more than 10% of body weight
- Skin rash, often with itching
- Tiredness and weakness
- Swollen legs or puffiness from fluid build-up
Immune and blood-related problems
| Problem | Possible signs |
|---|---|
| Autoimmune haemolytic anaemia | Tiredness, breathlessness, yellow eyes, dark urine |
| Low platelets | Easy bruising or bleeding |
| Raised antibodies (hypergammaglobulinaemia) | Found on blood tests; usually no symptoms |
| Eosinophilia | Found on blood tests; may add to itching |
| Arthritis-like symptoms | Painful or swollen joints |
| Infections | Frequent or unusual infections due to weakened immunity |
When to seek medical advice
See a doctor if you have swollen lymph nodes lasting more than a few weeks, a persistent rash with fever, or unexplained night sweats and weight loss.
Seek urgent help for high fever, breathlessness, severe weakness or yellowing of the skin.
6. Diagnosis
| Test | Purpose |
|---|---|
| Excision lymph node biopsy | Main test; shows the typical pattern |
| Immunohistochemistry | CD3, CD4, PD-1, CXCL13, ICOS, CD10, CD21, CD30 |
| EBV testing | EBER staining in tissue; EBV viral load in blood |
| T-cell receptor gene studies | Show a clonal (single-origin) T-cell population |
| Mutation testing | RHOA, TET2, IDH2 and DNMT3A support the diagnosis |
| PET-CT | Stage and extent of disease |
| Bone marrow biopsy | Sometimes needed for staging |
| Blood tests | Blood count, LDH, beta-2 microglobulin, immunoglobulins, Coombs test, hepatitis and HIV tests |
Staging
AITL is staged with the Lugano system, from stage I (one area) to stage IV (widespread, including organs such as bone marrow). Most people have stage III or IV at diagnosis (Federico et al., 2013).
Prognostic scores
| Score | Factors included |
|---|---|
| International Prognostic Index (IPI) | Age, stage, LDH, performance status, extranodal sites |
| AITL score | Age over 60, poor performance status, raised CRP and raised beta-2 microglobulin (Advani et al., 2021) |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Reactive lymph node swelling | No clonal T cells; TFH markers not abnormal |
| Classic Hodgkin lymphoma | Reed-Sternberg cells; different T-cell background |
| Peripheral T-cell lymphoma, NOS | Lacks the full TFH pattern |
| Drug reaction or viral infection | Settles once the cause is removed |
| Autoimmune disease | No lymphoma on biopsy |
7. Treatment
Treatment is planned by a specialist lymphoma team. It depends on age, fitness, stage and the results of tests such as CD30 expression.
First-line treatment
| Treatment | Notes |
|---|---|
| CHOP | Cyclophosphamide, doxorubicin, vincristine and prednisolone; the long-standing standard |
| CHOEP | CHOP plus etoposide; often used in fit people under 60 |
| BV-CHP | Brentuximab vedotin replacing vincristine; tested in CD30-positive PTCL, with the clearest benefit in ALCL (Horwitz et al., 2019) |
| Clinical trials | Encouraged because standard results are modest |
Chemotherapy is usually given as six cycles, every 2-3 weeks.
Stem cell transplant
Fit patients who reach a complete remission after first treatment may be offered high-dose chemotherapy with an autologous stem cell transplant (using their own stem cells). This aims to reduce the chance of relapse, although its benefit has not been proven in a randomised trial.
An allogeneic transplant (using donor cells) may be considered for younger patients after relapse.
Treatment of relapsed or refractory AITL
| Option | Notes |
|---|---|
| Hypomethylating drugs (azacitidine) | Particularly relevant because of TET2 changes; studied in the ORACLE trial (Dupuis et al., 2024) |
| Histone deacetylase inhibitors | Romidepsin or belinostat, depending on country |
| Brentuximab vedotin | For CD30-positive disease |
| Bendamustine, gemcitabine-based chemotherapy | Common salvage options |
| Lenalidomide, duvelisib, pralatrexate | Used in some countries or trials |
| Allogeneic transplant | Offers the best chance of long-term control for selected fit patients |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Chemotherapy visits | Usually a day-unit visit every 2-3 weeks, with tablets (prednisolone) for a few days at home |
| Blood tests | Before each cycle to check that blood counts have recovered |
| Preventive medicines | Often antiviral tablets and antibiotics to prevent infections |
| Mid-treatment scan | A PET-CT after a few cycles to check the response |
| Transplant (if planned) | Stem cell collection, then about 3-4 weeks in hospital |
| Recovery | Tiredness can last several months after treatment ends |
Many people can continue light daily activities between cycles. It is important to contact the hospital immediately if you develop a temperature of 38 C or more, because infections can become serious quickly.
Supportive care
| Problem | Support |
|---|---|
| Infections | Antibiotic, antiviral and antifungal prevention; vaccinations |
| Autoimmune anaemia | Steroids; sometimes rituximab |
| Itching and rash | Creams, antihistamines; usually improves with lymphoma treatment |
| Low blood counts | Growth factor injections, transfusions |
| Fluid build-up | Drainage if needed |
Side effects
| Treatment | Possible side effects |
|---|---|
| CHOP-type chemotherapy | Hair loss, nausea, infections, nerve tingling, tiredness |
| Doxorubicin | Possible heart damage; heart tests before treatment |
| Brentuximab vedotin | Nerve damage (numbness or tingling), low blood counts |
| Stem cell transplant | Severe infections, mouth sores, prolonged tiredness |
8. Outlook (prognosis)
AITL is a serious lymphoma, but some people stay in remission for many years.
| Measure | Approximate outcome |
|---|---|
| 5-year overall survival | About 32-44% in large international studies (Federico et al., 2013; Advani et al., 2021) |
| 5-year progression-free survival | About 30% |
| Low-risk AITL score | 5-year survival over 60% |
| High-risk AITL score | 5-year survival around 20% or lower |
| After relapse | Survival is usually measured in months to a few years |
Older age, poor fitness, high LDH and high beta-2 microglobulin are linked to a less favourable outlook.
These numbers come from groups of people treated in the past and cannot predict what will happen to one person. Newer treatments, including drugs that target the gene changes typical of AITL, are being tested and may improve results in future.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits | Check for symptoms and swollen nodes, usually every 3-6 months at first |
| Blood tests | Blood counts, LDH, immunoglobulins |
| Scans | When symptoms or tests suggest relapse |
| Heart checks | After doxorubicin |
| Vaccinations | Advice on flu, COVID-19 and pneumococcal vaccines; avoid live vaccines during treatment |
10. Living with AITL
- Report fever immediately during treatment
- Protect your skin: use gentle soaps and moisturisers if the rash is itchy
- Keep active as far as you can; light exercise helps with tiredness
- Eat well and ask for a dietitian if weight loss is a problem
- Ask about clinical trials, which give access to new treatments
- Seek emotional support from your team, support groups or lymphoma charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is AITL a type of leukaemia? | No. It is a lymphoma, although it can affect the blood and bone marrow |
| Is it caused by EBV? | EBV is often present, but it is not thought to be the main cause |
| Is it inherited? | No |
| Can it be cured? | Some people achieve long-term remission, especially after a transplant |
| Why did my rash appear first? | Skin rash is a common early sign of the immune disruption in AITL |
| Can AITL go away on its own? | Symptoms sometimes fluctuate, and short spontaneous improvements have been described, but the lymphoma needs treatment |
| Will I lose my hair? | Usually yes with CHOP-type chemotherapy; it grows back after treatment |
| Can I work during treatment? | Some people can work part-time; tiredness and infection risk often make a break necessary |
| What is CD30 and why does it matter? | A marker on some lymphoma cells; if present, brentuximab vedotin may be an option |
12. Questions to ask your care team
- What is my stage and prognostic score?
- Is my lymphoma CD30-positive?
- Am I a candidate for a stem cell transplant?
- Are there clinical trials I can join?
- How can I reduce my risk of infections?
- What happens if the lymphoma comes back?
Resources
- Advani, R.H. et al. (2021) ‘Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project’, Blood, 138(3), pp. 213-220.
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Dupuis, J. et al. (2024) ‘Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study’, The Lancet Haematology, 11(6), pp. e406-e414.
- Federico, M. et al. (2013) ‘Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project’, Journal of Clinical Oncology, 31(2), pp. 240-246.
- Horwitz, S. et al. (2019) ‘Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial’, The Lancet, 393(10168), pp. 229-240.
- Lunning, M.A. and Vose, J.M. (2017) ‘Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma’, Blood, 129(9), pp. 1095-1102.
- Mourad, N. et al. (2008) ‘Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials’, Blood, 111(9), pp. 4463-4470.
- National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.